Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI

作者：Falong Zou, Shenghe Deng, Bo Liu, Mian Chen, D Chen, Jun Wang, Junnan Gu, Fuwei Mao, Yinghao Cao, Kailin Cai · 发表于：BMC Cancer · 年份：2025 · DOI：10.1186/s12885-025-14852-z · 被引用次数：4 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Gut microbiota and health、Immune cells in cancer

BACKGROUND: Inflammation significantly affects the progression of gastric cancer (GC). The Systemic Inflammation Response Index (SIRI) is an emerging prognostic marker for various malignant tumors, including GC. However, the mechanisms by which SIRI influences patient outcomes remain unclear. This study employed a multi-omics approach to analyze GC patients with different SIRI levels, aiming to identify factors underlying differences in prognosis. METHODS: A cohort of 495 GC patients was classified into high SIRI (n = 276) and low SIRI (n = 219) groups using a threshold of 2.6. Kaplan-Meier analysis and Receiver operating characteristic (ROC) curves were used to assess survival outcomes and the predictive accuracy of SIRI compared to other inflammatory markers. Gut microbiota and untargeted metabolomics analyses were conducted on stool samples from 45 GC patients, including 21 with high SIRI and 24 with low SIRI. RESULTS: Elevated SIRI levels were significantly associated with worse OS (P = 0.004, HR = 1.845, 95% CI: 1.231-2.766) and DFS (P < 0.0001, HR = 3.102, 95% CI: 2.016-4.772) in GC patients. Multi-omics analysis revealed distinct gut microbial and metabolic profiles between high- and low-SIRI subgroups. High SIRI was linked to increased Escherichia-Shigella and decreased levels of Blautia and Klebsiella. Metabolomic differences included elevated N-Acetylcadaverine and Epsilon-caprolactam, and decreased S-(PGA2)-glutathione. Integrative analysis identified significant m...